MLCI vs NBIX · rev $53.6M vs P/E 45, rev $1.77B
Mount Logan Capital Inc. Common Stock (MLCI) versus Neurocrine Biosciences Inc (NBIX) — a side-by-side from cached financials, not a winner call.
Mount Logan Capital Inc. Common Stock (MLCI) is a asset management company listed on NASDAQ.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Latest reported MLCI revenue for 2025-12-31 was $53.6M. Net income was -$60.8M. Revenue was up 7.6% from 2024-12-31 to 2025-12-31. MLCI currently screens at market cap $30.8M.
Latest reported NBIX revenue for 2026-06-30 was $1.77B. Net income was $342.3M. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
MLCI currently screens at market cap $30.8M. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Not investment advice. Open the MLCI and NBIX stock pages for the full models.
Not investment advice.